CymaBay Therapeutics Inc. (NASDAQ:CBAY) Director Kurt Von Emster sold 108,876 shares of the company’s stock in a transaction dated Tuesday, October 3rd. The stock was sold at an average price of $7.85, for a total value of $854,676.60. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Kurt Von Emster also recently made the following trade(s):

  • On Friday, September 29th, Kurt Von Emster sold 211,124 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $8.09, for a total value of $1,707,993.16.

Shares of CymaBay Therapeutics Inc. (CBAY) traded up 0.65% during mid-day trading on Wednesday, reaching $7.72. The company had a trading volume of 777,875 shares. The firm’s 50-day moving average is $6.85 and its 200 day moving average is $5.44. CymaBay Therapeutics Inc. has a 12 month low of $1.15 and a 12 month high of $8.45. The company’s market capitalization is $337.80 million.

CymaBay Therapeutics (NASDAQ:CBAY) last announced its quarterly earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.06). On average, equities research analysts predict that CymaBay Therapeutics Inc. will post ($0.82) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/04/cymabay-therapeutics-inc-cbay-director-kurt-von-emster-sells-108876-shares.html.

Large investors have recently modified their holdings of the company. Bank of New York Mellon Corp boosted its holdings in shares of CymaBay Therapeutics by 0.8% during the second quarter. Bank of New York Mellon Corp now owns 17,344 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 140 shares during the period. ClariVest Asset Management LLC bought a new stake in shares of CymaBay Therapeutics during the first quarter worth approximately $105,000. LVM Capital Management Ltd. MI boosted its holdings in shares of CymaBay Therapeutics by 100.0% during the second quarter. LVM Capital Management Ltd. MI now owns 20,000 shares of the biopharmaceutical company’s stock worth $115,000 after acquiring an additional 10,000 shares during the period. Marshall Wace North America L.P. bought a new stake in shares of CymaBay Therapeutics during the second quarter worth approximately $242,000. Finally, Ardsley Advisory Partners boosted its holdings in shares of CymaBay Therapeutics by 66.2% during the second quarter. Ardsley Advisory Partners now owns 50,210 shares of the biopharmaceutical company’s stock worth $290,000 after acquiring an additional 20,000 shares during the period. Institutional investors own 25.91% of the company’s stock.

CBAY has been the subject of several recent analyst reports. Piper Jaffray Companies restated an “overweight” rating and set a $12.00 target price on shares of CymaBay Therapeutics in a research note on Tuesday, July 25th. Cantor Fitzgerald restated a “buy” rating and set a $16.00 target price on shares of CymaBay Therapeutics in a research note on Tuesday, September 26th. Oppenheimer Holdings, Inc. increased their target price on CymaBay Therapeutics from $8.00 to $15.00 and gave the company an “outperform” rating in a research note on Thursday, July 20th. Citigroup Inc. restated an “outperform” rating and set a $15.00 target price (up previously from $8.00) on shares of CymaBay Therapeutics in a research note on Thursday, July 20th. Finally, Ifs Securities restated a “strong-buy” rating on shares of CymaBay Therapeutics in a research note on Monday, July 17th. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $12.69.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Receive News & Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.